Nimotuzumab
19/291-2075
Phase 2 small_molecule completed
Quick answer
Nimotuzumab for Esophageal Cancer is a Phase 2 program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chinese University of Hong Kong
- Indication
- Esophageal Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed